52 related articles for article (PubMed ID: 19782110)
1. Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.
Giraldo MA; Arevalo-Pinzon G; Rojas-Caraballo J; Mongui A; Rodriguez R; Patarroyo MA
Vaccine; 2009 Dec; 28(1):7-13. PubMed ID: 19782110
[TBL] [Abstract][Full Text] [Related]
2. Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.
Bouillet LÉ; Dias MO; Dorigo NA; Moura AD; Russell B; Nosten F; Renia L; Braga EM; Gazzinelli RT; Rodrigues MM; Soares IS; Bruna-Romero O
Infect Immun; 2011 Sep; 79(9):3642-52. PubMed ID: 21730090
[TBL] [Abstract][Full Text] [Related]
3. Poly I:C elicits broader and stronger humoral and cellular responses to a
Costa-Gouvea TBL; Françoso KS; Marques RF; Gimenez AM; Faria ACM; Cariste LM; Dominguez MR; Vasconcelos JRC; Nakaya HI; Silveira ELV; Soares IS
Front Immunol; 2024; 15():1331474. PubMed ID: 38650939
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates.
Zhang Y; Liu F; Zhao Y; Yang F; Bai J; Jia X; Roobsoong W; Sattabongkot J; Cui L; Cao Y; Luo E; Wang M
Parasit Vectors; 2021 Aug; 14(1):407. PubMed ID: 34399829
[TBL] [Abstract][Full Text] [Related]
5. Platform for Plasmodium vivax vaccine discovery and development.
Valencia SH; Rodríguez DC; Acero DL; Ocampo V; Arévalo-Herrera M
Mem Inst Oswaldo Cruz; 2011 Aug; 106 Suppl 1(Suppl 1):179-92. PubMed ID: 21881773
[TBL] [Abstract][Full Text] [Related]
6. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.
Fox CB; Baldwin SL; Vedvick TS; Angov E; Reed SG
Clin Vaccine Immunol; 2012 Oct; 19(10):1633-40. PubMed ID: 22896687
[TBL] [Abstract][Full Text] [Related]
7. Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax.
Yadava A; Waters NC
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005164. PubMed ID: 28081149
[No Abstract] [Full Text] [Related]
8. Plasmodium vivax: who cares?
Galinski MR; Barnwell JW
Malar J; 2008 Dec; 7 Suppl 1(Suppl 1):S9. PubMed ID: 19091043
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a Plasmodium vivax vaccine based on the duffy binding protein formulated using adjuvants compatible for use in humans.
Martinez FJ; Guillotte-Blisnick M; Huon C; England P; Popovici J; Laude H; Arowas L; Ungeheuer MN; Reimer JM; Carter D; Reed S; Mukherjee P; Chauhan VS; Chitnis CE
Sci Rep; 2023 Aug; 13(1):13904. PubMed ID: 37626150
[TBL] [Abstract][Full Text] [Related]
10. Progress towards the development of a
De SL; Ntumngia FB; Nicholas J; Adams JH
Expert Rev Vaccines; 2021 Feb; 20(2):97-112. PubMed ID: 33481638
[TBL] [Abstract][Full Text] [Related]
11. Sterile protection against
Obaldía N; Da Silva Filho JL; Núñez M; Glass KA; Oulton T; Achcar F; Wirjanata G; Duraisingh M; Felgner P; Tetteh KK; Bozdech Z; Otto TD; Marti M
Life Sci Alliance; 2024 Mar; 7(3):. PubMed ID: 38158220
[TBL] [Abstract][Full Text] [Related]
12. Carbon nanotubes as a novel tool for vaccination against infectious diseases and cancer.
Gottardi R; Douradinha B
J Nanobiotechnology; 2013 Sep; 11():30. PubMed ID: 24025216
[TBL] [Abstract][Full Text] [Related]
13.
da Veiga GTS; Moriggi MR; Vettorazzi JF; Müller-Santos M; Albrecht L
Front Immunol; 2022; 13():910236. PubMed ID: 36726991
[TBL] [Abstract][Full Text] [Related]
14. PvMSP8 as a Novel
Villasis E; Garro K; Rosas-Aguirre A; Rodriguez P; Rosado J; Gave A; Guzman-Guzman M; Manrique P; White M; Speybroeck N; Vinetz JM; Torres K; Gamboa D
Pathogens; 2021 Mar; 10(3):. PubMed ID: 33801386
[TBL] [Abstract][Full Text] [Related]
15. Two 20-Residue-Long Peptides Derived from
Ricaurte-Contreras LA; Lovera A; Moreno-Pérez DA; Bohórquez MD; Suárez CF; Gutiérrez-Vásquez E; Cuy-Chaparro L; Garzón-Ospina D; Patarroyo MA
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562650
[No Abstract] [Full Text] [Related]
16. What Is Known about the Immune Response Induced by
López C; Yepes-Pérez Y; Hincapié-Escobar N; Díaz-Arévalo D; Patarroyo MA
Front Immunol; 2017; 8():126. PubMed ID: 28243235
[TBL] [Abstract][Full Text] [Related]
17. A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions.
Hostetler JB; Sharma S; Bartholdson SJ; Wright GJ; Fairhurst RM; Rayner JC
PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004264. PubMed ID: 26701602
[TBL] [Abstract][Full Text] [Related]
18. Molecular Evolution of PvMSP3α Block II in Plasmodium vivax from Diverse Geographic Origins.
Gupta B; Reddy BP; Fan Q; Yan G; Sirichaisinthop J; Sattabongkot J; Escalante AA; Cui L
PLoS One; 2015; 10(8):e0135396. PubMed ID: 26266539
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and antigenicity of Plasmodium vivax merozoite surface protein 10.
Cheng Y; Wang B; Sattabongkot J; Lim CS; Tsuboi T; Han ET
Parasitol Res; 2014 Jul; 113(7):2559-68. PubMed ID: 24764159
[TBL] [Abstract][Full Text] [Related]
20. Low genetic diversity and functional constraint in loci encoding Plasmodium vivax P12 and P38 proteins in the Colombian population.
Forero-Rodríguez J; Garzón-Ospina D; Patarroyo MA
Malar J; 2014 Feb; 13():58. PubMed ID: 24533461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
